Routine management of locally advanced cervical cancer with concurrent radiation and cisplatin. Five-year results

Abstract

Background: Globally, cervical cancer primarily affects socially disadvantaged women. Five randomized trials were the foundation for adopting cisplatin-based chemotherapy during radiation as the standard of care for high-risk patients after primary radical hysterectomy who require adjuvant radiation and for locally advanced patients treated with definitive radiation. These results were obtained in clinical trials performed in carefully prepared academic centers; hence, we sought to determine whether these results could be reproduced when patients were treated on an out-of-protocol basis.

Evaluation of Role of Concurrent Chemotherapy and Brachytherapy in Locally Advanced Cervical Cancer Patients

“…In our study dose of cisplatin 35 mg/m 2 was used on weekly basis as radiosensitizer it is little lower side because review of this reports also shows that only 67% of patients completed 6 cycle of plane chemotherapy due to acute toxicity of chemotherapy [11]. Punushapai et al [12].…”

Cancer Cérvico Uterino Estadio Iiib Tratado Con Radioquimioterapia Concomitante Basada en Cisplatino: Experiencia Inicial Hospital Carlos Van Buren

“…Nuestros resultados de sobrevida global con un 55,6% a 3 años es similar a la informada en otras series internacionales (15,16,29) en estadío IIIB.…”

Srinagarind Hospital experience in concurrent chemoradiation for 100 patients with stage IB2 to IVA uterine cervical cancer

“…External beam radiation consisted of 5000 cGy to the whole pelvis delivered in 25 daily fractions over 5 weeks using high-energy photons (10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25) with an additional 600-1000 cGy boost to the sides of grossly involved parametrium. Pelvic radiotherapy was delivered without the use of a midline block if the mass was larger than 5 cm.…”